Article: Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
AuthorsMan, K2
Zhao, Y1 2
Xu, A2
Lo, CM2
Lam, KSL2
Ng, KT2
Ho, JWY2
Sun, CK2
Lee, TK2
Li, XL2
Fan, ST2
KeywordsAnti-steatosis
Cell survival signaling
Hepatic microcirculation
Liver transplantation
Marginal graft
Issue Date2006
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
CitationAmerican Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
AbstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
ISSN1600-6135
2011 Impact Factor: 6.394
2011 SCImago Journal Rankings: 0.636
DOIhttp://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
ISI Accession Number IDWOS:000235224200005
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorMan, K
dc.contributor.authorZhao, Y
dc.contributor.authorXu, A
dc.contributor.authorLo, CM
dc.contributor.authorLam, KSL
dc.contributor.authorNg, KT
dc.contributor.authorHo, JWY
dc.contributor.authorSun, CK
dc.contributor.authorLee, TK
dc.contributor.authorLi, XL
dc.contributor.authorFan, ST
dc.date.accessioned2010-09-06T07:43:02Z
dc.date.available2010-09-06T07:43:02Z
dc.date.issued2006
dc.description.abstractOwing to the discrepancy between organ donation and the demand for liver transplantation, expanding the liver donor pool is of vital importance. However, marginal liver grafts, such as small-for-size and/or fatty grafts, were associated with primary graft nonfunction or poor function. Therefore, novel combination therapies to rescue small-for-size fatty liver grafts should be investigated. In this study, we applied a combination therapy using a fat-derived hormone adiponectin (anti-steatosis) plus immunomodulator FTY720 (anti-inflammatory) in a rat liver transplantation model using small-for-size fatty liver grafts, and investigated the underlying protective mechanism such as anti-steatosis, intra-graft energy metabolism, hepatic microcirculatory changes, cell signaling cascades for survival, apoptosis and inflammation. The current study demonstrated that even a single treatment of adiponectin or FTY720 improved the 7-day graft survival from 0% to 62.5% (p = 0.001). The combination therapy significantly increased the 7-day graft survival rate to 100% by remarkable attenuation of graft steatosis and acute phase inflammatory response, significant activation of cell survival Akt pathway and maintenance of intra-graft adenosine triphosphate metabolism and improvement of hepatic microcirculation. In conclusion, the fat-derived hormone adiponectin combined with FTY720 might be a novel combination drug therapy for prevention of small-for-size fatty liver graft injury. © 2006 The American Society of Transplantation and the American Society of Transplant Surgeons.
dc.description.naturelink_to_subscribed_fulltext
dc.identifier.citationAmerican Journal Of Transplantation, 2006, v. 6 n. 3, p. 467-476 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
dc.identifier.citeulike503077
dc.identifier.doihttp://dx.doi.org/10.1111/j.1600-6143.2005.01201.x
dc.identifier.epage476
dc.identifier.hkuros116888
dc.identifier.isiWOS:000235224200005
dc.identifier.issn1600-6135
2011 Impact Factor: 6.394
2011 SCImago Journal Rankings: 0.636
dc.identifier.issue3
dc.identifier.openurl
dc.identifier.pmid16468955
dc.identifier.scopuseid_2-s2.0-33644885246
dc.identifier.spage467
dc.identifier.urihttp://hdl.handle.net/10722/78451
dc.identifier.volume6
dc.languageeng
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
dc.publisher.placeDenmark
dc.relation.ispartofAmerican Journal of Transplantation
dc.relation.referencesReferences in Scopus
dc.rightsThe definitive version is available at www.blackwell-synergy.com
dc.subject.meshFatty Liver - pathology - surgery
dc.subject.meshGraft Rejection - blood - drug therapy - pathology
dc.subject.meshGraft Survival - drug effects
dc.subject.meshImmunosuppressive Agents - therapeutic use
dc.subject.meshLiver Transplantation
dc.subjectAnti-steatosis
dc.subjectCell survival signaling
dc.subjectHepatic microcirculation
dc.subjectLiver transplantation
dc.subjectMarginal graft
dc.titleFat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival
dc.typeArticle
Author Affiliations
  1. China Medical University Shenyang
  2. The University of Hong Kong